Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Online Access: | https://doi.org/10.1186/s13223-023-00805-3 |
| _version_ | 1827916843773329408 |
|---|---|
| author | Paul K. Keith Juthaporn Cowan Amin Kanani Harold Kim Gina Lacuesta Jason K. Lee Jie Chen Michelle Park André Gladiator |
| author_facet | Paul K. Keith Juthaporn Cowan Amin Kanani Harold Kim Gina Lacuesta Jason K. Lee Jie Chen Michelle Park André Gladiator |
| author_sort | Paul K. Keith |
| collection | DOAJ |
| first_indexed | 2024-03-13T03:21:03Z |
| format | Article |
| id | doaj.art-556b947c3ffe4bfa8229937e7530d558 |
| institution | Directory Open Access Journal |
| issn | 1710-1492 |
| language | English |
| last_indexed | 2024-03-13T03:21:03Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Allergy, Asthma & Clinical Immunology |
| spelling | doaj.art-556b947c3ffe4bfa8229937e7530d5582023-06-25T11:20:04ZengBMCAllergy, Asthma & Clinical Immunology1710-14922023-06-011911410.1186/s13223-023-00805-3Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world studyPaul K. Keith0Juthaporn Cowan1Amin Kanani2Harold Kim3Gina Lacuesta4Jason K. Lee5Jie Chen6Michelle Park7André Gladiator8Division of Clinical Immunology and Allergy, Department of Medicine, McMaster UniversityDivision of Infectious Diseases, Department of Medicine, Department of Biochemistry, Microbiology, and Immunology; Centre for Infection, Immunity and Inflammation, University of Ottawa, The Ottawa Hospital Research InstituteDivision of Allergy and Clinical Immunology, Department of Medicine, St. Paul’s Hospital, University of British ColumbiaDivision of Clinical Immunology and Allergy, Department of Medicine, McMaster UniversityDepartment of Medicine, Dalhousie UniversityChair of Toronto Allergists and Evidence Based Medical EducatorTakeda Development Center Americas, Inc.Takeda Development Center Americas, Inc.Glattpark‑Opfikon, Takeda Pharmaceuticals International AGhttps://doi.org/10.1186/s13223-023-00805-3 |
| spellingShingle | Paul K. Keith Juthaporn Cowan Amin Kanani Harold Kim Gina Lacuesta Jason K. Lee Jie Chen Michelle Park André Gladiator Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study Allergy, Asthma & Clinical Immunology |
| title | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_full | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_fullStr | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_full_unstemmed | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_short | Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study |
| title_sort | correction transitioning subcutaneous immunoglobulin 20 therapies in patients with primary and secondary immunodeficiencies canadian real world study |
| url | https://doi.org/10.1186/s13223-023-00805-3 |
| work_keys_str_mv | AT paulkkeith correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT juthaporncowan correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT aminkanani correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT haroldkim correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT ginalacuesta correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT jasonklee correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT jiechen correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT michellepark correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy AT andregladiator correctiontransitioningsubcutaneousimmunoglobulin20therapiesinpatientswithprimaryandsecondaryimmunodeficienciescanadianrealworldstudy |